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Biomarker development is a major focus of research in cancer as well as in other 
diseases. We seek biomarkers for many purposes, including risk assessment, screening, 
diagnosis and prognosis. New molecular technologies in particular promise to provide 
biomarkers that can inform about risk and help guide clinical decisions.
There are two basic statistical approaches for evaluating such biomarkers. The first 
models the risk of disease (or disease outcome) as a function of the biomarker(s) using, 
for example, logistic (or Cox) regression. The value of a marker is measured by its effect 
on risk. The second summarizes marker performance with classification performance 
measures such as sensitivity and specificity, predictive values and ROC curves. There is 
controversy about which approach is most appropriate. Moons and Harrell (1) argue in 
favor of risk models since ultimately the patient wants to know his risk given his 
biomarker measurement. On the other hand, Pepe et al. (2) emphasize that the public 
health value of a marker lies in the fraction of diseased subjects detected, i.e., sensitivity, 
and the fraction of non-diseased subjects falsely identified as diseased, i.e., 1-specificity. 
Both statistical approaches are frequently applied, often to the same data. However, the 
relationship between them is unclear. Of particular concern, the two approaches 
frequently yield apparently contradictory results. A marker that is strongly related to risk 
is often a poorly performing classifier. A marker that is a strong predictor of risk after 
controlling for other risk factors often adds little to them in terms of improving 
classification performance. 
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In this commentary, we present a new graphic, the Predictiveness Curve. It is useful for 
assessing the value of  a risk model when applied to the population. We also extend the 
plot to simultaneously evaluate the risks associated with a marker and the marker’s 
performance as a classifier. This integrated approach provides a more complete and 
comprehensive analysis than current practice.  
Data for Illustration 
We illustrate with data from the Prostate Cancer Prevention Trial (PCPT) recently 
reported in this journal (3). 5519 men on the placebo arm of the study underwent prostate 
biopsy and had at least 2 PSA measurements in the 3 years prior to biopsy. Along with 
PSA and PSA change over time, data on family history of prostate cancer, results of 
digital rectal exam (DRE), age, ethnicity and prior biopsy were used to model the risk of 
finding prostate cancer and the risk of high grade disease (Gleason ≥ 7) at the time of 
prostate biopsy. Since the data are used only for illustrating a statistical method, in the 
interests of being relatively brief  we restrict the analysis to high grade disease, although 
a similar approach could be used for all prostate cancer. Of the 5519 men, 4.7% 
ultimately were found to have high grade disease. Table 1 shows the results of the logistic 
regression analysis. For the diagnosis of high grade disease, PSA, DRE, age and prior 
negative biopsy appeared to be predictive of risk.
The Predictiveness Curve 
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We can calculate an individual’s risk given data on his risk factors using the fitted risk 
model. For the prostate cancer example,the calculation (3) is 
)}exp(1/{)exp(diseasegradehighofrisk YY +=
where
biopsy)prior(37.0)positiveDRE(99.0age03.0PSAlog30.194.5 −+++−=Y
This risk calculator of Thompson et al (3) is available online at 
http://www.compass.fhcrc.org/edrnnci/bin/calculator/main.asp . We calculated the risk 
for each of the individuals in the PCPT study. The Predictiveness Curve in Figure 1 
shows the distribution of risks. To create the curve we ordered the risks from lowest to 
highest and plotted their values. We see that at 90% on the x-axis the risk value is 0.104. 
This indicates that 90% of subjects in the cohort have risks below 0.104 and only 10% 
have risks above 0.104.
Another way of using the graph is to start at a risk value on the y-axis and to read the 
corresponding percent on the x-axis. For example, at risk = 0.20 we see that the percent is 
97.8%. That is, 2.2% of subjects in the cohort have risks above 0.20. At risk =0.02 the 
percent is 39.0%, indicating that 39.0% of subjects in the cohort have risks below 0.02. 
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What does the graph offer that is not summarized in Table 1? It shows the range and 
distribution of risk levels associated with the model when it is applied to the population 
from which the cohort was drawn. Consider that an individual wants to use his calculated 
risk in deciding whether or not to have a biopsy. The decision is more straightforward if 
his risk of disease is close to 0 or 1. If his calculated risk is in an equivocal range, it is not 
helpful. Suppose, for illustration, that 20% risk of high grade disease is sufficiently high 
to recommend a biopsy and that 2% risk is sufficiently low to decide against biopsy. 
Individuals whose risks are calculated in the range (0.02,0.20) are unsure about whether 
or not they should have a biopsy obtained. (A formal cost-benefit analysis that 
incorporates their risk of disease might be helpful, although specifying costs and benefits 
is always difficult.) A risk model will be most useful for individual decision making if 
calculated risks of having high-grade disease tend to exceed 20% or be less than 2%. We 
see from Figure 1 however that the prostate cancer risk model leaves the majority of men, 
58.8%, in the indecisive risk region. Alternative thresholds might be chosen for defining 
high and low risk. If it is reasonable to assume that a man with a <5% risk of high grade 
disease may defer further evaluation while a man with a >10% risk would prefer an 
evaluation, the corresponding  indecisive risk region would contain only 25% of  the 
population. It is important to keep in mind however, that individuals typically do not 
distinguish between minor variations in risk so we prefer to use the more extreme 
definitions of low and high risk in our illustrations. 
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Different risk models can be compared through their Predictiveness Curves. In figure 2 
we see that the Predictiveness Curve for PSA alone is almost identical to that of the more 
comprehensive model that includes the additional risk factors of age, prior biopsy, family 
history and DRE. Both models calculate risks less than the 0.02 low risk threshold for 
36% and 39% of the population, respectively. At the high risk end of the scale, the PSA 
model puts 1.2% of subjects above the 0.20 risk level while the more comprehensive 
model puts 2.2% of subjects in the high risk range. For comparison we also include a 
simulated marker with much better performance. The simulated marker (SIM) identifies 
68.1% of subjects as low risk, 6.0% as high risk and leaves 25.9% with calculated risks in 
the equivocal (0.02,0.20) range. This marker was simulated as a standard normal random 
variable for controls and a normal (mean = 2 , standard deviation = 1) random variable 
for cases. 
Another approach to comparing risk models is with the R-squared statistic generalized 
from linear to logistic regression (4). The values 0.053, 0.066 and 0.310 for PSA alone, 
for PSA and other factors and for SIM, respectively, corroborate the results depicted in 
the Predictiveness curves. However the interpretation of the R-squared value as the 
proportion of the variance in disease explained by the model is not very intuitive. We 
have recently provided a more understandable interpretation as the difference in the 
average risks between diseased and non-diseased subjects (5).  Interestingly, R2 can be 
calculated as a summary index from the Predictiveness Curve 
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where ȡ = disease prevalence in the study population and Pred(v) is the value of the risk 
at the vth percentile. The denominator term in R2 is a standardization factor leading to 
values in the range 0 (useless prediction) to 1 (perfect prediction). We find the display of 
the Predictiveness curve more useful than simply reporting its R2 summary index. 
In our plots we include a horizontal line located at the risk level equal to the prevalence. 
This corresponds to the Predictiveness Curve for a completely uninformative risk model, 
one that assigns all subjects equal risk. It serves as a reference curve. Moreover, 
mathematically the positive area above the horizontal line but below the Predictiveness 
Curve must equal the negative area below the horizontal line but above the Predictiveness 
curve. Better markers will show larger positive and negative areas and we find the 
horizontal line a helpful visual aid. 
Classification Based on Risk 
Clinical decision criteria are often of the form “marker ≥ threshold.” For example, the 
criterion “PSA ≥ 4.0 ng/ml” has been used to recommend biopsy. However, decision 
criteria might be better formulated in terms of risk. For example, the criterion “risk ≥
0.20” could be used to recommend biopsy. Criteria formulated in terms of risk are natural 
and intuitive. In addition, they are statistically optimal in the sense that they minimize 
false positive and false negative error rates, a notion defined precisely in (6).
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The performance of decision rules based on a risk model can be calculated from the 
model’s Predictivness Curve. We illustrate in Figure 3. For example, the positive 
predictive value of the criterion “risk > threshold” is the proportion of the dark 
area in the shaded rectangle that lies under the curve. The true positive fraction 
corresponding to this criterion is the same dark area under the curve divided by the 
prevalence of disease. Although exact calculations will be made directly from the data, 
approximate calculations can be made by simply viewing the Predictiveness Curve. 
An Integrated Approach 
The plot shown in Figure 4a is a comprehensive summary of the population performance 
of the risk model based on SIM, the simulated marker. It allows one to assess decision 
criteria from multiple points of view. For example, we see that by recommending biopsy 
for subjects with risks above 0.20, 6% of the population proceed to biopsy, 57% of 
subjects with high-grade disease are detected, while 3.4% of subjects without high-grade 
disease are unnecessarily biopsied. The choice of threshold might be dictated by 
controlling one or more of the performance measures. Maintaining the false positive 
fraction (1-specificity) at a low level is paramount in primary screening, while a high true 
positive fraction (sensitivity) is often crucial in diagnostic settings. Yet the corresponding 
risk threshold will also be an important aspect to consider in order to ensure that 
decisions are satisfying to individuals. To illustrate, in Figure 4b, if we choose the 
positivity criterion on the basis of a true positive fraction (TPF) =0.95 say, the 
corresponding risk threshold is 0.013. Sending individuals for biopsy when their risks are 
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as low as 0.013 may be inappropriate. In addition we see that the corresponding false 
positive fraction is unacceptably high, FPF=37%. 
DISCUSSION
The fitting of risk models to biomarker and risk factor data is a valuable exercise. 
However, the usefulness of the model as applied to the population is rarely evaluated. We 
suggest for this purpose the Predictiveness Curve, a display of the risk distribution 
revealed by the biomarkers and risk factors in the population. A desirable model performs 
a triage process, placing most individuals at high or low risk values, where decisions are 
more easily made. In developing a biomarker, we need to define reasonable thresholds 
for high and low risk, thresholds that depend on the clinical context. The Predictiveness 
Curve then shows the capacity of the marker to identify meaningful variations in risk. By 
simultaneously displaying predictiveness and classification performance with the 
Integrated plot, we believe that biomarker researchers are better equipped to understand 
the potential utility of a risk model applied in the population. This practical goal 
motivated our research. 
One must always be cautious to interpret a risk model and its Predictiveness Curve in the 
context of the population that gave rise to the data. Strictly speaking the ‘population' 
refers to a population for which the available cohort is representative subsample. As 
noted by Thompson et al (3), PCPT participants may not reflect the general U.S. 
population. Subjects in the PCPT study were participants in a clinical trial. They may 
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differ from the general population because of eligibility criteria, characteristics related to 
their self-selection for the study and their care during the course of the study. Therefore 
their risk model may not apply with complete fidelity to the general population. We use 
the data here simply to illustrate statistical methodology and for that purpose it serves 
well. Nevertheless it raises questions about risk assessment using research cohorts in 
general, and clinical trial cohorts in particular. Although they may provide a useful 
starting point for marker evaluation and marker comparison, ultimately risk models 
should be calculated on cohorts representative of the population.
The analyses we applied to the PCPT data showed that additional risk factors do not add 
substantially to the predictiveness of PSA alone, in that the fraction of subjects in the 
equivocal risk range is not appreciably decreased. A risk factor can have a large effect on 
risk, but if it is rare in the population, it cannot substantially influence population risk 
prediction. In the PCPT, few subjects have risk factor levels that substantially change 
their risk calculated on the basis of PSA alone. For only 72 subjects did their risk change 
from <0.2 to >0.2 and, not surprisingly, a positive DRE accounted for most of these 
(92%). Nevertheless, the fact that the risk model has limitations on a population level 
does not mean that it won’t contribute in a meaningful way to the biopsy decision-making 
process of some individuals, which was the specified purpose of developing the risk 
model (3).
The predictiveness curve is easy to calculate once a risk model has been fitted. We have 
developed procedures for constructing confidence intervals and for comparing points on 
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two curves under cross-sectional cohort designs (5). Bootstrap techniques can also be 
applied. For case-control study designs it is possible to estimate risk from a fitted logistic 
regression if the disease prevalence is known. Corresponding procedures to estimate the 
predictiveness curve from case-control data are currently under development. For settings 
with an outcome variable that is a time to an event, such as disease or death, one can 
define risk as a function of time, i.e., the probability of an event in a time interval (0,t). 
Predictiveness curves would be plotted for different time intervals. 
Using the same dataset to fit a risk model and to assess its performance can lead to 
optimistic estimates of model performance. This is an issue particularly when many 
predictors are involved. Cross-validation or bootstrapping can be applied in these settings 
to correct for this bias. In our analysis of the PCPT data, the model that included other 
risk factors in addition to PSA showed minimal improvement over PSA alone with 
uncorrected Predictiveness Curves, so correcting for bias was unnecessary. 
We note that fitting an adequate risk model is an ambitious statistical task, more 
ambitious than estimating an ROC curve, for example. The former is akin to estimating a 
probability density while the latter is akin to estimating a cumulative distribution 
function. Therefore, with small datasets where risk modeling is not feasible one might 
proceed to simply evaluating the usual classification performance measures such as the 
ROC curve. With larger datasets, classification performance measures should also be 
assessed but perhaps in conjunction with the predictiveness curve in order to integrate the 
risk modeling and classification approaches to data analysis. 
http://biostats.bepress.com/uwbiostat/paper289
REFERENCES
(1) Moons KGM, Harrell FE. Sensitivity and specificity should be de-emphasized in 
diagnostic accuracy studies. Academ Radiol 2003;10:670–672. 
(2) Pepe MS, Janes H, Longton G, Wendy Leisenring W, Newcomb P. Limitations of the 
odds ratio in gauging the performance of a diagnostic, prognostic, or screening 
marker. Am J Epidem 2004;159:882–890. 
(3) Thompson IM, Pauler Ankerst D, Chi C, Goodman P, Tangen C, Lucia MS, Feng Z, 
Coltman CA. Screen-based prostate cancer risk: results from the prostate cancer 
prevention trial. J Natl Ca Inst 2006; 98: 529-534. 
(4) Mittlebock M, Schemper M. Explained variation for logistic regression. Stat Med 
1996;15:1987–1997.
(5) Ying Huang, Margaret S. Pepe, and Ziding Feng, Evaluating the Predictiveness of a 
Continuous Marker.  UW Biostatistics Working Paper Series. Working Paper 282.  
http://www.bepress.com/uwbiostat/paper282. 
(6)  McIntosh M, Pepe MS. Combining several screening tests: optimality of the risk 
score. Biometrics 2002;58:657–664. 
Hosted by The Berkeley Electronic Press
Captions.
Table 1. Logistic regression analysis of risk for high grade disease  as reported in 
Thompson et al (3).
Figure 1. Predictiveness curve for the risk model shown in Table 1 that includes PSA, 
age, prior biopsy, family history and DRE as risk factors for high grade prostate cancer. 
Figure 2. Predictiveness Curves for PSA alone, PSA and other factors and the simulated 
(SIM) marker. 
Figure 3. Schematic diagram showing how classifier performance parameters relate to 
the Predictiveness Curve. Positive Predictive Value=dark/shade dark + intermediate; 
Negative Predictive Value = white area/white + light shade; True Positive Fraction = dark 
shade/dashed box; False Positive Fraction=intermediate shade/1-dashed box. 
Figure 4. The integrated predictiveness and classification plot for the simulated marker 
using two criteria for defining a positive biomarker result. Criterion (a) is risk >0.20. 
Criterion (b) is TPF=0.95. 
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Table 1 
Factor Log Odds Ratio P-value
logPSA 1.30 <0.001 
Age (years) 0.03 0.02 
DRE 0.99 <0.001 
Prior biopsy –0.37 0.04 
Constant –5.94 — 
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